CD30-targeted Oncolytic Viruses as Novel Therapeutic Approach Against Classical Hodgkin Lymphoma

Oncotarget- United States

doi 10.18632/oncotarget.24191

Full Text

Abstract

Available in

Categories

Date

January 12, 2018

Authors

Julia D.S. Hanauer

Benjamin Rengstl

Dina Kleinlützum

Thorsten Friedel

Irene C. Schneider

Sebastian Newrzela

Martin- Leo Hansmann

Christian J. Buchholz

Publisher

Impact Journals, LLC

Related search

Novel Therapeutic Agents for Relapsed Classical Hodgkin Lymphoma

British Journal of Haematology

English

Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma

Frontiers in Immunology

English

Novel Treatment Strategies for Patients With Relapsed Classical Hodgkin Lymphoma

English

Lymphocyte-Rich Classical Hodgkin Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Cancer Research

German

Targeted Genotyping of Circulating Tumor DNA for Classical Hodgkin Lymphoma Monitoring: A Prospective Study

English

An Anaplastic T-Cell Lymphoma Mimicking Classical Hodgkin Lymphoma

English

Targeted Genotyping of Circulating Tumor Dna for Classical Hodgkin Lymphoma Monitoring: A Prospective Study

Hematological Oncology

Cancer Research

English

Armed Therapeutic Viruses: Strategies and Challenges to Arming Oncolytic Viruses With Therapeutic Genes

Cancer Gene Therapy

Cancer Research

Molecular Medicine

Molecular Biology

English

Circulating Dendritic Cells Deficiencies as a New Biomarker in Classical Hodgkin Lymphoma

British Journal of Haematology

English